期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

来氟米特的作用机制及临床应用进展 被引量：13

The action mechanism and advances in clinical application of leflunomide
下载PDF
导出
摘要 来氟米特是一种新型的免疫抑制剂,主要用于类风湿性关节炎的治疗。近年的一些临床研究提示,该药物对其他自身免疫性疾病也有一定的疗效。本文综述来氟米特的作用机制和临床研究进展,阐述其最新研究动态和发展趋向。 Leflunomide is a new immunosuppressant which has been mainly used in treating rheumatoid arthritis.Recently a lot of clinical studies showed that leflunomide was also effective to treat other autoimmunologic diseases. The action mechanism and advances in clinical application of leflunomide are reviewed. [
作者 韩星海 刘彧 施冶青 赵东宝 蔡青 管剑龙 闾坚强
机构地区 第二军医大学长海医院风湿免疫科
出处 《药学服务与研究》 CAS CSCD 2004年第3期243-246,共4页 Pharmaceutical Care and Research
关键词 来氟米特 药动学 作用机制 临床应用 leflunomide pharmacokinetics mechanism clinical application
分类号 R976 [医药卫生—药品]
  • 相关文献

参考文献26

  • 1[1]Smolen JS,Kalden JR,Scott DI,et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised,multicentre trial[J]. Lancet, 1999, 353(9149): 259.
  • 2[2]Cherwinski HM, Byars N, Ballaron SJ, et al. Leflunomide interferes with pyramidine nucleotide biosynthesis [J].Inflamm Res, 1995, 44(8): 317.
  • 3[3]Herrmann M, Frangou CG, Kirschbaum B. Cell cycle control of the de novo pyrimidine synthesis inhibitor leflunomide through the p53 and p21WAF-1 pathways[J].ACR Poster Session,2000, Abstract: 875.
  • 4[4]Xu X, Williams JW, Gong H, et al. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726.Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation[J]. Biochem Pharmacol, 1996, 52(4): 527.
  • 5[5]Klausner RD, Samelson LE. T cell antigen receptor activation pathway: the tyrosine kinase connection[J]. Cell,1991, 64(5): 875.
  • 6[6]Mattar T, Kochhar K, Bartlett R, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide[J]. FEBS Lett, 1993, 334(2): 161.
  • 7[7]Shawver LK, Schwartz DP, Mann E, et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N- [4- (trifluoromethyl) -phenyl] 5-methylisoxazole -4- carboxamide[J]. Clin Cancer Res, 1997,3(7): 1167.
  • 8[8]Xu X, Shen J, Mall JW , et al. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide:mechanisms of action[J]. Biochem Phamacol, 1999, 58(9):1405.
  • 9[9]Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726 ) blocks TNF-dependent nuclear factor-κB activation and gene expression [J]. J Immunol, 1999, 162(4): 2095.
  • 10[10]Tomita N, Morishita R, Lan HY, et al. In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis[J]. J Am Soc Nephrol, 2000, 11(7): 1244.

二级参考文献5

共引文献77

同被引文献135

引证文献13

二级引证文献91

药学服务与研究
2004年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部